Publications

Use the search tool below to browse peer-reviewed published articles on or related to Jazz's approved and investigational products. Please note, publications related to Jazz's approved product may contain information about dosing or use of a Jazz product that is different from the approved use(s). Jazz does not recommend the use of any of its products in any manner that listed in the product Prescribing Information, which is displayed as part of this search tool. Publications on Jazz's investigational products are provided for information only. Under no circumstances does Jazz promote use of a product without a licensed indication. If you have any questions about information in a publication or wish to access a publication not listed below, please contact Jazz Medical Information via the link below.

Product

Clear selection Defitelio® (defibrotide) Epidiolex® (cannabidiol) Rylaze® (asparaginase erwinia chrysanthemi (recombinant) rywn) injection Vyxeos® (daunorubicin and cytarabine) Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII Ziihera® (zanidatamab) Zepzelca® (lurbinectedin)

Filter by keywords

Publication

Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.

Published: February 13, 2023

Authors: Melissa Sandley, Jonathan Angus

Publication

Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity.

Published: February 13, 2023

Authors: Evan C Rosenberg, Simon Chamberland, Michael Bazelot et al.

Publication

Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program.

Published: January 10, 2023

Authors: Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez et al.

Publication

Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam.

Published: November 25, 2022

Authors: Rohini R Rana, Karthik Rajasekaran, Volker Knappertz et al.

Publication

Clinical considerations for the diagnosis of idiopathic hypersomnia.

Published: October 31, 2022

Authors: Yves Dauvilliers, Richard K Bogan, Isabelle Arnulf et al.

Publication

Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia.

Published: October 26, 2022

Authors: Michael J Thorpy, Isabelle Arnulf, Nancy Foldvary-Schaefer et al.

Publication

Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.

Published: September 06, 2022

Authors: Yves Dauvilliers, Isabelle Arnulf, Nancy Foldvary-Schaefer et al.

Publication

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.

Published: May 31, 2022

Authors: Richard K Bogan, Michael J Thorpy, Yves Dauvilliers et al.

Publication

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.

Published: May 30, 2022

Authors: Yves Dauvilliers, Karel Šonka, Richard K Bogan et al.

Publication

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.

Published: April 09, 2022

Authors: Orrin Devinsky, Anup D Patel, J Helen Cross et al

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.